- IL 17 Signaling Pathway信号通路图库
- CART疗法中的小明星——免疫调节因子IL7
- IL4signalingpathway资讯
- 大家来说说国产的常规核酸提取试剂盒 生物科学 小木虫论坛...
- 可以推荐一个家用的制冰机吗?
- Case Haldor Topsoe PR electr...
- 二代妖精之今生有幸 (豆瓣) Douban
- 蒙古航空的点评和航班 Tripadvisor
- ChaperonesmodulateinterferonSi...
- www.www.tongjiacademy.bayermat...
- NuclearReceptorsinLipidMetabol...
- 由RNA组成的酶是 什么 酶?
- [02-04]我的信号通路研究 实验方法
- [11-21]NFKB通路专题讨论
- [05-21]细胞信号通路大全
- [07-22]检测蛋白磷酸化的六种方法及其优缺点 企业动态
- [07-24]各位大佬,我要研究一个信号通路,涉及到三个因子 细胞技术讨论版 丁...
- [01-16]常见的信号转导通路
- [02-13]概述受体酪氨酸激酶(PTK)介导的信号通路的组成、特点及其主要功能。
- [02-09]求细胞信号通路图制作方法或软件
- [02-06]【求助】研究细胞膜分子下游信号转导通路的方法和思路? 实验方法 ...
Inhibition of Cellular Proliferation by Gleevec
ThedrugGleevec(alsoknownasimatinibmesylateorSTI-571)wasapprovedbytheFDAin2001forthetreatmentofCML,chronicmyeloidleukemia.WhiletrADItionalcytotoxiccancertreatmentssuchaschemotherapyorradiationtherapykillalldividingcells,Gleevecactsonamoleculartargetbyamechanismthatismorespecifictocancercells.Traditionalcytotoxiccanceragentshaveserioussideeffectssuchasnausea,weightloss,hairlossandseverefatiguethatresultfromtheirlackofspecificityinkillingcells.GleevecwasdesignedasaninhibitorofaspecificreceptorassociatedwithCML,andsoproduceslessseveresideeffectsthanothercanceragents.CMLisassociatedinmostcaseswithaspecificchromosomaldefect,atranslocationbetweenchromosomes9and22thatcreatesthePhiladelphiachromosome.Thistranslocationoccursatthesiteinthegenomeofaproteintyrosinekinasecalledabl,creatingtheabnormalbcr-ablprotein,afusionoftheablgenewithanothergenecalledbcr.Thekinaseactivityofablinthebcr-ablfusionisactivatedandunregulated,drivingtheuncontrolledcellgrowthobservedinCML.Whitebloodcellscontainingthebcr-ablmutationbecomeabletoproliferateintheabsenceofgrowthfactorstheynormallyrequire.Gleevecinhibitsablkinaseactivity,helpingtoreverseuncontrolledcellgrowth.GleevecalsoinhibitsthePDGFtyrosinekinaseandthec-kittyrosinekinase.Thereareavarietyofcellularsubstratesofthebcr-ablkinasethatmaybeinvolvedincellulartransformation.Bcr-ablisassociatedwiththecytoplasmaspartofalargesignalingcomplex.Someofthedownstreamfactorsinbcr-ablsignalingincludePI3kinase/AKTandSTATtranscriptionfactors.Theactivationofbcr-ablalsorepressesapoptosisthroughinductionofanti-apoptosisfactorssuchasBad,allowingtransformedcellstodivide.JAK2kinaseactivityappearstobeonetargetofbcr-abl.Grb-2phosphorylationbybcr-ablmayplayaroleindown-regulationoftyrosinekinasesignaling.STAT5maybeinvolvedinthefailureofapoptosisinbcr-ablcells.Inadditiontosupportingtheideathatcancertherapiestargetingspecificmoleculartargetsshouldbeefficaciouswithfewersideeffects,Gleevechasalsodemonstratedthatdrugsinhibitingproteinkinasescanbedevelopedsuccessfully.Tyrosinekinasesareimportantinarangeofcellularprocesses,includingothercancers,andwillprovideadditionaldrugtargets.Gleevecitselfhasalreadydemonstratedpotentialinothercancerssuchasgastrointestinalstromaltumorthatdonotrespondtoexistingtreatments.AlthoughGleevechasproducedverystrongclinicalresponsesinpatientswithearlystageCML,patientswithlatestagediseasehavehadaninitialresponsefollowedbyarelapseofdrugresistantCMLcells.CancercellsinpatientswithGleevecresistantcancereitherhadamplificationofthebcr-ablgene,ormutationofakeyaminoacidinvolvedinbindingdrugfromthreoninetoisoleucine.
Contributor:
REFERENCES:FletcherL.(2001)Approvalheraldsnewgenerationofkinaseinhibitors?Nat.Biotechnol.,19(7):599-600Gorre,M.E.etal.(2001)ClinicalresistancetoSTI-571cancertherapycausedbyBCR-ABLgenemutationoramplification.Science293:876-880;Mauro,M.J.,Druker,B.J.(2001)STI571:targetingBCR-ABLastherapyforCML.Oncologist6(3),233-8Pestell,K.(2001)Anti-cancerdrugsuccessemergesfrommolecularBIOLOGyorigins.TrendsPharmacol.Sci.,22(7),342Sattler,M.,Griffin,J.D.(2001)MechanismsoftransformationbytheBCR/ABLoncogene.IntJHematol73(3),278-91Xie,S.etal.(2001)InvolvementofJak2tyrosinephosphorylationinBcr-Abltransformation.Oncogene,20(43),6188-95
================ 蚂蚁淘在线 ================
免责声明:本文仅代表作者个人观点,与本网无关。其创作性以及文中陈述文字和内容未经本站证实,对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺,请读者仅作参考,并请自行核实相关内容
版权声明:未经蚂蚁淘在线授权不得转载、摘编或利用其他方式使用上述作品。已经经本网授权使用作品的,应该授权范围内使用,并注明“来源:蚂蚁淘在线”。违反上述声明者,本网将追究其相关法律责任。